U.S. Markets closed
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • Dow 30

    33,290.08
    -533.37 (-1.58%)
     
  • Nasdaq

    14,030.38
    -130.97 (-0.92%)
     
  • Russell 2000

    2,237.75
    -49.71 (-2.17%)
     
  • Crude Oil

    71.50
    +0.46 (+0.65%)
     
  • Gold

    1,763.90
    -10.90 (-0.61%)
     
  • Silver

    25.84
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1865
    -0.0045 (-0.3797%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • Vix

    20.70
    +2.95 (+16.62%)
     
  • GBP/USD

    1.3809
    -0.0115 (-0.8272%)
     
  • USD/JPY

    110.1500
    -0.0810 (-0.0735%)
     
  • BTC-USD

    35,688.59
    -19.12 (-0.05%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

Citius Pharmaceuticals to Present Corporate Update at Benzinga Global Small Cap Conference on December 8

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

CRANFORD, N.J., Dec. 3, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today announced that it will be participating in the Benzinga Global Small Cap Conference being held virtually on December 8 and 9, 2020. Citius Chairman Leonard Mazur will present at 11:30 am ET on Tuesday, December 8, 2020, and will host one-on-one investor meetings.

Advanced investor registration for the conference and virtual one-to-one meeting requests can be accessed here.

We are currently advancing four proprietary product candidates: Mino-Lok®, CITI-002 (halobetasol-lidocaine formulation or Halo-Lido), CITI-101 (Mino-Wrap), and CITI-401 (iMSC). Mr. Mazur will discuss recent Company developments for these product candidates including:

  • Mino-Lok® is advancing in its Phase 3 trial

  • A positive second interim analysis report from the independent Drug Monitoring Committee (DMC) for the Mino-Lok pivotal Phase 3 trial

  • The signing of an exclusive worldwide license agreement with Novellus Therapeutics, Limited for a cellular therapy to treat acute respiratory distress syndrome (ARDS), a leading complication of COVID-19; and the formation of our Novecite, Inc. subsidiary.

  • Submission of a pre-investigational new drug (PIND) consultation request for Mino-Wrap with written response and guidance is expected

  • Update on Halo-Lido which is anticipated to begin Phase 2b trial in the first quarter of 2021

About Citius Pharmaceuticals, Inc.

Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit www.citiuspharma.com.

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks associated with conducting clinical trials and drug development; our dependence on third-party suppliers; our need for substantial additional funds; patent and intellectual property matters; market and other conditions; our ability to attract, integrate, and retain key personnel; the estimated markets for our product candidates and the acceptance thereof by any market; risks related to our growth strategy; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:
Andrew Scott
Vice President, Corporate Development
(O) 908-967-6677 x105
(M) 646-522-8410
ascott@citiuspharma.com

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-corporate-update-at-benzinga-global-small-cap-conference-on-december-8-301186114.html

SOURCE Citius Pharmaceuticals, Inc.